fig4

 <i>ROS1</i> mutations promote an immunosuppressive tumor microenvironment via <i>MYC</i> to confer immune evasion in head and neck cancer

Figure 4. Molecular differences in immune cell composition and immune-related gene expression between ROS1-WT and ROS1-Mut tumors in the TCGA HNC cohort. (A) Comparison of 22 predefined immune cell types; (B) expression of 39 immune-related genes. *P < 0.05; **P < 0.01; ns: not significant (P ≥ 0.05). ROS1-WT: ROS1-wild-type; ROS1-Mut: ROS1 mutations; TCGA: The Cancer Genome Atlas; HNC: head and neck cancer.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/